Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC phase 3 trial of abelacimab in high-risk atrial fibrillation patients unsuitable for oral anticoagulation
MOH_2023-02-16_012341Phase 3Not yet recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Abelacimab 150 mg monthly with Matching placebo monthly (2 arms). Primary endpoint: Ischemic stroke or systemic embolism. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on MOH_2023-02-16_012341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-16_012341.